Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of TK216 in Patients With Relapsed and Refractory Leukemias

Next Previous
Trial Profile

Phase I Study of TK216 in Patients With Relapsed and Refractory Leukemias

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs TK 216 (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 21 Nov 2018 Status changed from planning to not yet recruiting.
    • 07 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top